Improving bladder cancer treatment by targeting DNA repair deficiencies
Official title: Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
Funded at Dana-Farber Cancer Inst · NIH-10918108 · Data updated 2026-11-12
This study is looking at how certain gene changes in people with muscle-invasive bladder cancer might help doctors decide the best treatment options, like whether to remove the bladder or use a combination of chemotherapy and radiation, to improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $411,213 |
| NIH project number | 5R01CA272657-03 |
| Project ID | NIH-10918108 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with muscle-invasive bladder cancer, particularly those with ERCC2 mutations.
✕Less likely to help
Patients with non-muscle-invasive bladder cancer or those without ERCC2 mutations may not benefit from this research.
What this research studies
This research investigates how deficiencies in the nucleotide excision repair (NER) pathway, specifically mutations in the ERCC2 gene, affect treatment outcomes for patients with muscle-invasive bladder cancer (MIBC). The study aims to determine if these mutations can serve as molecular biomarkers to guide treatment decisions between bladder removal and bladder-sparing chemoradiotherapy. By analyzing patient responses to cisplatin-based chemotherapy and clinical chemoradiotherapy regimens, the research seeks to enhance personalized treatment approaches for MIBC patients. The methodology includes examining tumor samples and treatment responses to identify patterns linked to ERCC2 mutations.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with muscle-invasive bladder cancer.
How similar studies have gone: Previous research has shown that targeting DNA repair deficiencies can improve treatment responses in other cancers, suggesting potential success for this approach in bladder cancer.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Mouw, Kent W — Dana-Farber Cancer Inst
- Study coordinator: Mouw, Kent W
Related research
Other NIH-funded projects on the same topics.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
-
Body fats and immune signals shaping bladder cancer outlook
This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.
-
Novel combination immunotherapy for non–muscle-invasive bladder cancer
Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.
-
Why some bladder cancers don't respond to BCG treatment
This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.
-
Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy
A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.